-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] The Science and Technology Innovation Board is a high-tech and strategic emerging sector.
There are many innovative regulations in terms of issuance and trading.
Since the gong opened in July 2019, the Science and Technology Innovation Board has attracted a lot of "hard" Technology" pharmaceutical companies and investors' eyes
.
According to statistics, there were 15 pharmaceutical companies listed on the Science and Technology Innovation Board in 2019, 26 in 2020, and 38 in 2021, a record number
.
Since the beginning of this year, the Science and Technology Innovation Board has continued to welcome the listing of pharmaceutical companies
.
For example, recently, Xuantai Medicine has successfully listed on the Science and Technology Innovation Board.
The issue price is 9.
37 yuan, 45.
34 million shares are issued, and the total amount of funds raised is 425 million yuan
.
It is understood that Xuantai Pharmaceutical's opening price on the first day was 15.
8 yuan, up 68.
6% from the issue price; the closing price was 13.
6 yuan, up 45% from the issue price; based on the closing price, the company's market value was 6.
165 billion yuan
.
Xuantai Pharmaceutical is mainly engaged in the research and development, production and sales of generic drugs and CRO services.
In the field of generic drugs, the company has obtained bupropion hydrochloride sustained-release tablets, propafenone hydrochloride sustained-release capsules, posaconazole enteric-coated tablets, ANDA drug approvals for 4 generic drugs including paroxetine hydrochloride enteric-coated sustained-release tablets
.
On August 18, United Imaging Medical announced that the company's shares will be listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange on August 22, 2022
.
The issuance price of United Imaging Medical is 109.
88 yuan per share.
After the completion of this issuance, the total number of shares is 824,157,988 shares, and the price-earnings ratio is 77.
69 times
.
After the successful issuance, the market value of United Imaging Medical is expected to reach 90.
5 billion yuan
.
United Imaging Medical is committed to providing global customers with high-performance medical imaging equipment, radiotherapy products, life science instruments and medical digital and intelligent solutions.
The product line covers MR products, CT products, XR products, MI products and RT products as well as life scientific instruments,
etc.
At the end of last year, United Imaging Medical's application for listing on the Science and Technology Innovation Board was accepted, with a financing amount of 12.
48 billion yuan and a proposed issuance value of 104.
1 billion yuan
.
On August 5, Mengke Pharmaceutical also officially listed on the Science and Technology Innovation Board
.
According to the prospectus, Mengke Pharmaceutical plans to issue 130,000,000 new shares at an issue price of 8.
16 yuan per share.
After the issuance, its total number of shares is 655,210,084 shares, of which 118,687,659 shares without circulation restrictions and sales restrictions will be issued in August 2022.
It can be listed and traded on the secondary market from May 5
.
Through this IPO, Mengke Pharmaceutical has raised a total of 1.
061 billion yuan, and after deducting the issuance cost of 101 million yuan, the net amount of funds raised is 960 million yuan
.
The raised funds will be mainly used for innovative drug research and development projects, marketing channel upgrades and academic promotion projects, and projects to supplement working capital
.
Entering 2022, in addition to the above companies, many pharmaceutical companies such as Maiwei Bio and Asieris have already landed on the Science and Technology Innovation Board
.
In addition, there are more than 20 IPOs of pharmaceutical companies on the way
.
According to this trend, the number of pharmaceutical companies on the Science and Technology Innovation Board may soon exceed 100
.
It is worth noting that in recent years, the regulatory authorities have frequently issued policies.
The industry expects that with the comprehensive advancement of the registration system, a series of new policies such as the Science and Technology Innovation Board, the Growth Enterprise Market, and the Beijing Stock Exchange will be implemented, and the IPO process of pharmaceutical companies will be further accelerated.
Or usher in a new round of capital tide
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
There are many innovative regulations in terms of issuance and trading.
Since the gong opened in July 2019, the Science and Technology Innovation Board has attracted a lot of "hard" Technology" pharmaceutical companies and investors' eyes
.
According to statistics, there were 15 pharmaceutical companies listed on the Science and Technology Innovation Board in 2019, 26 in 2020, and 38 in 2021, a record number
.
Since the beginning of this year, the Science and Technology Innovation Board has continued to welcome the listing of pharmaceutical companies
.
For example, recently, Xuantai Medicine has successfully listed on the Science and Technology Innovation Board.
The issue price is 9.
37 yuan, 45.
34 million shares are issued, and the total amount of funds raised is 425 million yuan
.
It is understood that Xuantai Pharmaceutical's opening price on the first day was 15.
8 yuan, up 68.
6% from the issue price; the closing price was 13.
6 yuan, up 45% from the issue price; based on the closing price, the company's market value was 6.
165 billion yuan
.
Xuantai Pharmaceutical is mainly engaged in the research and development, production and sales of generic drugs and CRO services.
In the field of generic drugs, the company has obtained bupropion hydrochloride sustained-release tablets, propafenone hydrochloride sustained-release capsules, posaconazole enteric-coated tablets, ANDA drug approvals for 4 generic drugs including paroxetine hydrochloride enteric-coated sustained-release tablets
.
On August 18, United Imaging Medical announced that the company's shares will be listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange on August 22, 2022
.
The issuance price of United Imaging Medical is 109.
88 yuan per share.
After the completion of this issuance, the total number of shares is 824,157,988 shares, and the price-earnings ratio is 77.
69 times
.
After the successful issuance, the market value of United Imaging Medical is expected to reach 90.
5 billion yuan
.
United Imaging Medical is committed to providing global customers with high-performance medical imaging equipment, radiotherapy products, life science instruments and medical digital and intelligent solutions.
The product line covers MR products, CT products, XR products, MI products and RT products as well as life scientific instruments,
etc.
At the end of last year, United Imaging Medical's application for listing on the Science and Technology Innovation Board was accepted, with a financing amount of 12.
48 billion yuan and a proposed issuance value of 104.
1 billion yuan
.
On August 5, Mengke Pharmaceutical also officially listed on the Science and Technology Innovation Board
.
According to the prospectus, Mengke Pharmaceutical plans to issue 130,000,000 new shares at an issue price of 8.
16 yuan per share.
After the issuance, its total number of shares is 655,210,084 shares, of which 118,687,659 shares without circulation restrictions and sales restrictions will be issued in August 2022.
It can be listed and traded on the secondary market from May 5
.
Through this IPO, Mengke Pharmaceutical has raised a total of 1.
061 billion yuan, and after deducting the issuance cost of 101 million yuan, the net amount of funds raised is 960 million yuan
.
The raised funds will be mainly used for innovative drug research and development projects, marketing channel upgrades and academic promotion projects, and projects to supplement working capital
.
Entering 2022, in addition to the above companies, many pharmaceutical companies such as Maiwei Bio and Asieris have already landed on the Science and Technology Innovation Board
.
In addition, there are more than 20 IPOs of pharmaceutical companies on the way
.
According to this trend, the number of pharmaceutical companies on the Science and Technology Innovation Board may soon exceed 100
.
It is worth noting that in recent years, the regulatory authorities have frequently issued policies.
The industry expects that with the comprehensive advancement of the registration system, a series of new policies such as the Science and Technology Innovation Board, the Growth Enterprise Market, and the Beijing Stock Exchange will be implemented, and the IPO process of pharmaceutical companies will be further accelerated.
Or usher in a new round of capital tide
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
